Literature DB >> 7586975

Anticardiolipin antibodies and antiphospholipid syndrome in chronic discoid lupus erythematosus.

A Ruffatti1, C Veller-Fornasa, G M Patrassi, E Sartori, M Tonello, S Tonetto, A Peserico, S Todesco.   

Abstract

Anticardiolipin antibodies (aCL) of immunoglobulin (Ig) G and M classes were determined in 28 patients affected with chronic discoid lupus erythematosus (CDLE), comparing their prevalence and levels to those in 60 healthy subjects matched for age and sex. A high and significant frequency of IgG (67.8%) and IgM (50.0%) aCL together with prevalence of high antibody levels was found in CDLE patients, while healthy controls had IgG and IgM aCL in 1.6% and 3.3% of cases respectively. Clinical features in keeping with the diagnosis of antiphospholipid syndrome were found in one patient (3.5%), which, as the first manifestation of the syndrome, showed a pulmonary thromboembolism which appeared some days after prolonged exposure to the sun. These results provide additional data on autoimmune phenomena in CDLE and suggest that aCL test should be considered as useful aids in immunological diagnosis of CDLE.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586975     DOI: 10.1007/BF02207672

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

1.  Antiphospholipid antibody syndrome.

Authors:  M D Lockshin
Journal:  JAMA       Date:  1992-09-16       Impact factor: 56.272

2.  [Anticardiolipin antibodies in cutaneous lupus erythematosus. Incidence and importance as a marker of vascular symptoms].

Authors:  B Tebbe; C E Orfanos
Journal:  Hautarzt       Date:  1992-03       Impact factor: 0.751

Review 3.  [Cutaneous lupus erythematosus and cardiolipin antibodies. Incidence and clinical significance].

Authors:  P Kind; H C Schuppe; K P Jung; K Degitz; H J Lakomek; G Goerz
Journal:  Hautarzt       Date:  1992-03       Impact factor: 0.751

Review 4.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

5.  A catastrophic antiphospholipid syndrome: the importance of high levels of warfarin anticoagulation.

Authors:  A Ruffatti; G De Silvestro; A Ghirardello; A Calligaro; T Del Ross; G Thiene; S Todesco
Journal:  J Intern Med       Date:  1994-01       Impact factor: 8.989

6.  Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation.

Authors:  P Lehmann; E Hölzle; P Kind; G Goerz; G Plewig
Journal:  J Am Acad Dermatol       Date:  1990-02       Impact factor: 11.527

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

Authors:  A E Gharavi; E N Harris; R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

  8 in total
  3 in total

Review 1.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 2.  Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology.

Authors:  C M Cale; L Morton; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 3.  Unusual manifestations of the antiphospholipid syndrome.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.